Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK PM reassures over AstraZeneca jab as under-30s offered alternative

Thu, 08th Apr 2021 06:34

(Alliance News) - Prime Minister Boris Johnson has sought to reassure the public the Oxford/AstraZeneca PLC vaccine is safe after UK regulators said there was a possible link between the jab and "extremely rare" blood clots.

The Medicines & Healthcare products Regulatory Agency said the benefits still outweigh the risks overall but while it has not concluded that the vaccine causes rare brain clots, it said the link is getting firmer.

Regulators have recommended that people aged 18 to 29 should be offered the Pfizer, Moderna or other vaccines that come on stream as the programme continues to rollout across the UK.

It comes as the family of a solicitor who died from a blood clot after receiving an AstraZeneca vaccine urged the public to "keep saving lives" by taking up a jab when offered it.

The prime minister sought to boost public confidence in the Oxford-developed shot as he said the changes in its use would not force a change in the road map out of lockdown.

Johnson told reporters in Cornwall: "These vaccines are safe, they've saved many thousands of lives and people should come forward to get their jabs and we'll make sure that they get the right jabs."

MHRA's chief executive Dr June Raine told a press conference that there was a "reasonably plausible" link between the AstraZeneca jab and rare blood clots, but stressed these were "extremely rare".

She said: "Based on the current evidence, the benefits of the Covid-19 vaccine AstraZeneca against Covid-19 and its associated risks – hospitalisation and death – continues to outweigh the risks for the vast majority of people.

"Our review has reinforced that the risk of this rare suspected side effect remains extremely small."

Meanwhile the family of Neil Astles, 59, who died in hospital on Easter Sunday after receiving his first AstraZeneca jab dose on March 17, told the Telegraph that they wanted the public to continue taking up the vaccine.

Dr Alison Astles told the newspaper: "If we all have the vaccine, a few of us might have a blood clot but the evidence is that fewer people will die.

"We trust the process, we trust the regulator, and despite what has happened to our family, we don't want people to be scared off. That's the message we want to get across."

A separate review by the European Medicines Agency (EMA) concluded on Wednesday that "unusual blood clots with low blood platelets should be listed as very rare side effects" of the AstraZeneca vaccine.

The MHRA said that up to March 31, across the UK it had received 79 reports of blood clots accompanied by low blood platelet count, all in people who had their first dose of the vaccine, out of around 20 million doses given.

Of these 79, a total of 19 people have died, the regulator said, although it has not been established what the cause was in every case. Of the 19 who died, three were under the age of 30.

The figures suggest the risk of rare blood clot is the equivalent to four people out of every million who receive the vaccine.

The MHRA said that those who have had their first dose of the AstraZeneca vaccine should still get their second dose.

Only those who suffered a rare blood clot after the first dose should not get vaccinated.

Anyone with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor before going for a jab.

In Europe, the EMA has carried out an in-depth review of 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis, in which 18 people died.

Health Secretary Matt Hancock said on Twitter that the findings by the MHRA and EMA had confirmed that the AstraZeneca jab was "safe" and that the benefits of the jab "far outweigh the risks for the vast majority of adults".

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Jul 2023 22:30

British prime minister seeks to win back corporate confidence with new business council

LONDON, July 17 (Reuters) - British Prime Minister Rishi Sunak will hold the first meeting of his new business council on Tuesday, in a bid to support his pledge to grow the economy and fend off attempts by the opposition Labour Party to win over the business community.

Read more
17 Jul 2023 19:33

US FDA approves AstraZeneca and Sanofi's Beyfortus for RSV in infants

(Alliance News) - AstraZeneca PLC and Sanofi SA on Monday said the US Food & Drug Administration has approved the use of Beyfortus, or nirsevimab, in the US.

Read more
14 Jul 2023 09:13

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
14 Jul 2023 08:56

LONDON MARKET OPEN: Stocks mixed ahead of US bank earnings

(Alliance News) - Stock prices in London opened mixed on Friday, after a strong run this week, while investors wait to see how major US banks fared in the second quarter of the year.

Read more
14 Jul 2023 07:56

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Read more
12 Jul 2023 12:08

Astra, Daiichi get China approval for Enhertu breast cancer treatment

(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday its metastatic breast cancer treatment with AstraZeneca PLC was approved in China as a monotherapy for adult patients.

Read more
12 Jul 2023 09:27

LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
12 Jul 2023 08:45

LONDON MARKET OPEN: FTSE 100 higher as UK banks pass BoE stress tests

(Alliance News) - European markets were trading higher on Wednesday, in a sign of cautious optimism ahead of US inflation data.

Read more
12 Jul 2023 07:40

LONDON BRIEFING: UK banks pass stress test; Wetherspoon trades well

(Alliance News) - Stocks in London are called higher on Wednesday, ahead of US inflation data.

Read more
10 Jul 2023 11:27

UK stocks: Even cheaper than normal

STOXX 600 up 0.1% after last week's rout

*

Read more
10 Jul 2023 09:14

STOXX stabilises after last week's slide

STOXX 600 mostly steady after last week's rout

*

Read more
7 Jul 2023 16:55

LONDON MARKET CLOSE: FTSE 100 ends rough week in tepid fashion

(Alliance News) - Stock prices in Europe diverged on Friday, with the FTSE 100 underperforming, as a weaker-than-expected US jobs report did little for equities amid the expectation that the Federal is not done with hiking.

Read more
5 Jul 2023 12:04

China extends squeezed-out foreign pharmaceuticals firms an olive branch

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market.

Read more
5 Jul 2023 09:34

LONDON BROKER RATINGS: UBS likes Pearson; Liberum cuts Naked Wine

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
4 Jul 2023 17:18

UK's FTSE 100 inches lower as industrials dip; healthcare stocks rebound

Airlines rise after strong numbers from giant Ryanair

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.